Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125273863 | 12527386 | 3 | F | 200604 | 20160718 | 20160705 | 20160801 | EXP | GB-PFIZER INC-2016193346 | PFIZER | 74.00 | YR | M | Y | 147.20000 | KG | 20160801 | CN | GB | GB |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125273863 | 12527386 | 1 | PS | CARDURA XL | DOXAZOSIN MESYLATE | 1 | 4 MG, 1X/DAY | Y | 19668 | 4 | MG | GASTRO-RESISTANT TABLET | QD | ||||||
| 125273863 | 12527386 | 2 | SS | CARDURA XL | DOXAZOSIN MESYLATE | 1 | 8 MG, 1X/DAY (2 X 4MG ) | Y | 00000372 | 19668 | 8 | MG | GASTRO-RESISTANT TABLET | QD | |||||
| 125273863 | 12527386 | 3 | SS | CARDURA XL | DOXAZOSIN MESYLATE | 1 | 12 MG, ONCE DAILY ( ISSUED AS 1 X 8 MG AND 1 C 4 MG TABLETS) | Y | 19668 | 12 | MG | GASTRO-RESISTANT TABLET | QD | ||||||
| 125273863 | 12527386 | 4 | SS | CARDURA XL | DOXAZOSIN MESYLATE | 1 | 16 MG, ONCE DAILY (2 X 8 MG TABLETS) | Y | 00000372 | 19668 | 16 | MG | GASTRO-RESISTANT TABLET | QD | |||||
| 125273863 | 12527386 | 5 | C | GLUCOPHAGE | METFORMIN HYDROCHLORIDE | 1 | 500 MG, 4X/DAY (TAKEN 2 TWICE A DAY WITH FOOD) | 0 | 500 | MG | QID | ||||||||
| 125273863 | 12527386 | 6 | C | ALPHACALCIDOL | ALFACALCIDOL | 1 | 250 NG, DAILY | 0 | 250 | NG | CAPSULE | ||||||||
| 125273863 | 12527386 | 7 | C | BISOPROLOL | BISOPROLOL | 1 | 5 MG, 2X/DAY | 0 | 5 | MG | BID | ||||||||
| 125273863 | 12527386 | 8 | C | BISOPROLOL | BISOPROLOL | 1 | 0 | ||||||||||||
| 125273863 | 12527386 | 9 | C | CANDESARTAN | CANDESARTAN | 1 | 32 MG, DAILY | 0 | 32 | MG | TABLET | ||||||||
| 125273863 | 12527386 | 10 | C | CANDESARTAN | CANDESARTAN | 1 | 0 | TABLET | |||||||||||
| 125273863 | 12527386 | 11 | C | MOXONIDINE | MOXONIDINE | 1 | 200 UG, 1X/DAY | 0 | 200 | UG | TABLET | QD | |||||||
| 125273863 | 12527386 | 12 | C | BUMETANIDE. | BUMETANIDE | 1 | 1 MG, 3X/DAY (TAKE 3 EACH LUNCHTIME) | 0 | 1 | MG | TABLET | TID | |||||||
| 125273863 | 12527386 | 13 | C | BUMETANIDE. | BUMETANIDE | 1 | 0 | TABLET | |||||||||||
| 125273863 | 12527386 | 14 | C | SIMVASTATIN. | SIMVASTATIN | 1 | 20 MG, 1X/DAY (TAKEN AT NIGHT) | 0 | 20 | MG | TABLET | QD | |||||||
| 125273863 | 12527386 | 15 | C | SIMVASTATIN. | SIMVASTATIN | 1 | 0 | TABLET | |||||||||||
| 125273863 | 12527386 | 16 | C | WARFARIN | WARFARIN | 1 | 1 MG, 3MG, 5MG TABLETS TO BE TAKEN AS DIRECTED | 0 | TABLET | ||||||||||
| 125273863 | 12527386 | 17 | C | ZERODOUBLE | 2 | UNK (TO BE APPLIED TO THE AFFECTED PART REGULARLY) | 0 | GEL |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125273863 | 12527386 | 1 | Blood pressure management |
| 125273863 | 12527386 | 5 | Type 2 diabetes mellitus |
| 125273863 | 12527386 | 6 | Chronic kidney disease |
| 125273863 | 12527386 | 7 | Atrial fibrillation |
| 125273863 | 12527386 | 8 | Hypertension |
| 125273863 | 12527386 | 9 | Cardiac failure |
| 125273863 | 12527386 | 10 | Hypertension |
| 125273863 | 12527386 | 11 | Hypertension |
| 125273863 | 12527386 | 12 | Chronic kidney disease |
| 125273863 | 12527386 | 13 | Cardiac failure |
| 125273863 | 12527386 | 14 | Diabetes mellitus |
| 125273863 | 12527386 | 15 | Hypertension |
| 125273863 | 12527386 | 16 | Atrial fibrillation |
| 125273863 | 12527386 | 17 | Eczema |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125273863 | 12527386 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125273863 | 12527386 | Arthralgia | |
| 125273863 | 12527386 | Asthenia | |
| 125273863 | 12527386 | Atrial fibrillation | |
| 125273863 | 12527386 | Balance disorder | |
| 125273863 | 12527386 | Cerebral disorder | |
| 125273863 | 12527386 | Chronic kidney disease | |
| 125273863 | 12527386 | Depression | |
| 125273863 | 12527386 | Dizziness | |
| 125273863 | 12527386 | Dyspnoea | |
| 125273863 | 12527386 | Irritability | |
| 125273863 | 12527386 | Lacrimation increased | |
| 125273863 | 12527386 | Left ventricular failure | |
| 125273863 | 12527386 | Loss of libido | |
| 125273863 | 12527386 | Mental impairment | |
| 125273863 | 12527386 | Mobility decreased | |
| 125273863 | 12527386 | Mood swings | |
| 125273863 | 12527386 | Muscle fatigue | |
| 125273863 | 12527386 | Myalgia | |
| 125273863 | 12527386 | Pain in extremity | |
| 125273863 | 12527386 | Peripheral vascular disorder | |
| 125273863 | 12527386 | Prescribed overdose | |
| 125273863 | 12527386 | Pruritus | |
| 125273863 | 12527386 | Skin discolouration | |
| 125273863 | 12527386 | Skin irritation |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125273863 | 12527386 | 1 | 20031023 | 0 | ||
| 125273863 | 12527386 | 2 | 20040115 | 0 | ||
| 125273863 | 12527386 | 3 | 20060324 | 0 | ||
| 125273863 | 12527386 | 4 | 200604 | 20160318 | 0 | |
| 125273863 | 12527386 | 5 | 19980828 | 0 | ||
| 125273863 | 12527386 | 6 | 20100914 | 0 | ||
| 125273863 | 12527386 | 7 | 20100511 | 0 | ||
| 125273863 | 12527386 | 9 | 20141011 | 0 | ||
| 125273863 | 12527386 | 11 | 20081119 | 0 | ||
| 125273863 | 12527386 | 12 | 19970703 | 0 | ||
| 125273863 | 12527386 | 14 | 20070704 | 0 | ||
| 125273863 | 12527386 | 16 | 20050523 | 0 |